Member Info for celticnew

Is the Cloudtag.com website no longer working?

Also RIP to the Onitor.com website 😪😪😪😪😪

Licence and DaaP Payment Update

18th July 2024

19th July 2024

The Company would like to advise Shareholders holding paper certificates that the first tranche of notifications shall take place on 24th July.

The announcement of the DaaP sale shall be made on the 31st July by the buyer.

The Company remains under strict non-disclosure agreements. All further updates will be published on www.cloudtag.com

Dear Mr Glynn

Thanks for your message.

It's our understanding that two payments are due in the coming weeks but my colleagues in the Corporate Actions team will be writing to you with further information when they have it.

I hope this has been of assistance. If you have any further questions, please reply by secure message from your HL account or send us an email.

Kind regards

Andrew Gilbreeze

Hargreaves Lansdown

I wish !

This feels like the longest break up in history. A further delay until July. It's painful. And it's gone on for years. Sighs.

' I wouldn't want to be out of this over the weekend'. 🌞

I had well and truly written this off and if we do get anything back it would be a good bonus.

I am finding it odd though that this hasn't been picked up by the media. The company delists many years ago after much controversy etc. Then a statement is there on the website saying it's been sold for $275,000,000.

It surely deserves a mention if all is true. It wasn't worth tuppence when it delisted. Lol.

I really hope we get some kind of meaningful return on these many years of worry and disappointment. GLA

Hi all . Was just wondering if this thread has been previously discussed.

Tony Reeves [ Ex Cloudtag ] Currently N Ex Director at Bermele plc

3rd September 2019

Bermele Plc, a Company formed to acquire a target company (or companies) with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector

RTO ?

Also are there some ex Corvus on the board ?

Dear



We thank you for your interest in the Pre-IPO fundraise.



There are a few steps that need to be taken before we can register your full interest by sending out a subscription letter:



We need to establish you are a current shareholder of Cloudtag Inc. Please send proof by email,
Such proof should be a statement from your stock broker recently dated. We will also need copy of your passport and two utility bills not older than 3 months with proof of address and,
The amount you wish to invest under the pre IPO offer of 1p.


Full settlement of any investment must be made by the Friday 14th September 2018.



Thank you again for your interest and we look forward to hearing from you.



Kind regards,

Value of the offer a few minutes ago, based on live fx rates, was 5019p with 2325p in cash and 2694p in shares. With current share price of 4398p, the share price would need to rise 14.13% to match. From the original offer value of 4901p, we have lost 113p in value due to fall in value of Takeda shares but gained 231p because of favourable fx movements on both the cash and share elements. Takeda (Yen) = 4725 £:$ = 1.30424 £:Yen = 147.164

Value of the offer a few minutes ago, based on live fx rates, was 4972p with 2300p in cash and 2672p in shares. With current share price of 4332p, the share price would need to rise 14.78% to match. From the original offer value of 4901p, we have lost 109p in value due to fall in value of Takeda shares but gained 180p because of favourable fx movements on both the cash and share elements. Takeda (Yen) = 4730 £:$ = 1.31888 £:Yen = 148.494 My personal 'get out' price is £51.

Yes this is a hard one to call. Am hoping the deal will go through but there are many obstacles yet to overcome. I think Takeda have a vote at the end of the month so will be interested to see where it moves from there.

Osaka, Japan - June 8, 2018 - Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") announces that it has today entered into a term loan credit agreement for an aggregate principal amount of up to 7.5 billion USD with leading global financial institutions including J.P. Morgan Chase Bank N.A., Sumitomo Mitsui Banking Corporation, MUFG Bank, Ltd. and Mizuho Bank, Ltd. (the "Term Loan Credit Agreement"). The majority of the funding has been committed by Japanese institutions.

Takeda Pharmaceutical Co. is nearing an agreement to buy rival drugmaker Shire Plc, people familiar with the matter said, in what would mark the biggest ever takeover by the Japanese company. A deal agreement could be announced as early as Tuesday, the deadline set by U.K. regulators for Takeda to make a firm offer for Shire, according to the people, who asked not to be identified because the information is private. Recent negotiations have centered on the structure of the potential transaction, with Shire seeking an increase in the cash component of Takeda�s 46 billion-pound ($64 billion) bid, the people said. It wasn�t immediately clear if Takeda had consented to the request. Takeda reached a preliminary pact with Shire last month after offering the equivalent of about 49 pounds a share, including 27.26 pounds in stock and 21.75 pounds in cash. That�s a 60 percent premium to Shire�s closing price on March 27, before Takeda disclosed its takeover interest. Negotiations are ongoing, and an agreement could still be delayed, the people said. Takeda has also held preliminary talks with potential advisers about divestitures it may pursue if the Shire takeover is successful, according to the people. Representatives for Takeda and Shire declined to comment. Chief Executive Officer Christophe Weber is steering Takeda into its largest-ever transaction to replenish the drugmaker�s pipeline of medicines with promising treatments for rare diseases such as hemophilia -- a field that�s lured many pharmaceutical companies lately because they can charge more for unique life-saving drugs than for routine treatments. Takeda could face a multiple-step credit downgrade due to a �spike in leverage� if its proposed acquisition of Shire goes ahead, Moody�s Investors Service said last month.

Forthcoming Appointments 20th April 2018 Amit Ben-Haim, CEO of Cloudtag Inc. is pleased to report that the Company is in the process of recruiting a high level individual with multiple years of experience with UK private health care providers, whose role will be to assist the Company to broadcast its B2B offering, whilst opening commercial opportunities with UK private health care providers for its weight management digital health platform. Furthermore; the Company is recruiting a 3rd Board Advisor with an academic background in nutritional behaviour, who will supporting Cloudtag�s future clinical studies and be instrumental in the AI programme in relation to nutrition and behaviour changes.

Reference to Cloudtag in Royal Academy of Engineering report 16th April 2018 Amit Ben-Haim, CEO of Cloudtag Inc. comments that the company is pleased to have been mentioned in the Royal Academy of Engineering�s March 2018 Internet of Things report. Cloudtag has been mentioned in the security and risk management section relating to sector-specific challenges. Healthcare and medical devices The security of connected medical devices is a particular challenge, existing alongside the challenges of privacy, transparency, trust and the user�s autonomy. These include both implantable medical devices and medical-grade wearables. The latter often builds on existing consumer devices. For example, Apple�s new iWatch 3 has an enhanced heart feature. Startups such as CloudTag are targeting the NHS via medical-grade consumer devices aimed at the health, wellbeing and fitness markets.

Telit Announces World's First Category 11 LTE Full Mini PCIe Card Telit's new industrial-grade LM940 Mini Card is the first in its class embedded with Qualcomm® Snapdragon™ X12 LTE Modem supporting download speeds of up to 600 Mbps As the fastest LTE-Advanced Mini Card, the LM940 is available for immediate deployment (PRNewsfoto/Telit IOT Platforms) NEWS PROVIDED BY Telit 02:13 ET SHARE THIS ARTICLE LONDON, Aug. 21, 2017 /PRNewswire/ -- Telit, a global enabler of the Internet of Things (IoT), today announced the LM940, the world's first global Full PCI Express Mini Card (mPCIe) module for the router and gateway industry supporting LTE Advanced Category 11 (Cat 11) with speeds of up to 600 Mbps, available with various mobile network operator approvals in the fourth quarter of 2017. For more information on the LM940 mPCIe module, visit: http://www.telit.com/Cellular/4G_Modules/LM940_mPCIe_data_card/. The only enabling technology in an mPCIe form factor to support Cat 11 with the Snapdragon X12 LTE modem, the industrial-grade LM940 delivers significant flexibility and a competitive edge to original equipment manufacturers (OEM) looking to quickly deploy next generation products with an unrivaled user experience. Today, customers of router and gateway OEMs demand additional bandwidth and near instant network response times as applications like high definition video streaming with digital signage, commercial and enterprise failover needs and pop-up stores are becoming increasingly sophisticated. "This industrial-grade module from Telit supporting LTE Cat 11 with global coverage will be very attractive for equipment manufacturers looking to deploy the latest solutions now, especially in the router and gateway marketsupporting high-bandwidth dependent applications like digital signage," said Sam Lucero, senior principal analyst for IHS Markit, a global information provider. "As detailed in our June 2016 report on the industrial cellular IoT gateways market*, IHS Markit anticipates gateway shipments will rise from nearly two million shipped in 2016 to more than six million shipped in 2021. The value of these industrial cellular IoT gateways shipped in 2021 will slightly exceed USD $1.6 billion." "Telit extends its leadership again by delivering customers the latest releases in LTE Advanced technology that they can take to market today," says Manish Watwani, VP Global Product Marketing for Telit. "The LM940 is the only global product for the router and gateway segment that allows OEMs to immediately leverage the 3x carrier aggregation and the higher order modulation of the 256 QAM capabilities currently available amongst most mobile operator networks. Combined with an exceptional power efficiency platform, this is by far the ideal solution to enable commercial and enterprise applications in the router industry, such as branch office connectivity, LTE failover, digital

I sold like you in the low 40's . Its s huge gamble to go back in imho. Too much volatility - Risk outweighs reward on this one for me. GLA

Good call - I got out at similar levels. Far too volatile for me.

(Reuters) - The Irish government was granted a High Court order on Tuesday for the recapitalisation of Irish Life & Permanent , effectively nationalising the bancassurer with an immediate injection of 2.7 billion euros in state funds. What happ-ens now?

Irish Life investors reject capitalisation plans Link this Share this Digg Email Print Related Topics Funds » PICTURES World Cup Japan beat U.S. to win women's World Cup Slideshow J. Lo and Marc Anthony split Carla Bruni pregnant Harry Potter stars: Then & Now Drought ravages Somalia Editor's choice DUBLIN, JulY 20 | Wed Jul 20, 2011 4:20pm IST (Reuters) - Shareholders in Irish Life & Permanent have voted against state plans to pour up to 3.8 billion euros ($5.4 billion) into the bancassurer, meaning it would be effectively nationalised, the group's chairman said on Wednesday. "On the basis of the proxies voted in advance of this meeting the shareholders have clearly decided not to support the resolutions put forward by the board," David Cook told the Extraordinary General Meeting (EGM), to sustained applause from around 300 shareholders. Some investors stood as they clapped. "Whilst I am disappointed to a degree by this outcome I am not surprised," said Cook. Irish Life & Permanent has to be recapitalised by the end of July under the terms of an EU-IMF bailout and the finance minister can trigger the recapitalisation without shareholder approval by applying to the courts. ($1 = 0.705 Euros) (Reporting by Carmel Crimmins; Editing by Erica